The takeaway
Survodutide showed promising weight results in a short diabetes trial, alongside more treatment-stopping side effects. The doses and study design matter when interpreting the comparison.
Who was studied?
Researchers randomized 413 adults with type 2 diabetes taking metformin; 411 received treatment. Eight groups tested six survodutide regimens, placebo, or semaglutide for 16 weeks. Blood sugar was the primary outcome; weight was secondary.
Percent of starting weight; secondary outcome
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Survodutide 1.8 mg twice weekly | 8.7% |
| Semaglutide 1.0 mg once weekly | 5.3% |
What changed?
Estimated average weight loss reached 8.7% with survodutide 1.8 mg twice weekly, versus 5.3% with semaglutide 1.0 mg weekly. These are selected groups, not results for every survodutide dose.
Across all survodutide groups, 15.9% stopped treatment because of adverse events, compared with 4.0% on semaglutide and 5.1% on placebo. Digestive symptoms were common.
What limits the comparison?
Participants knew when they received semaglutide. Survodutide doses increased rapidly, and the study was short. This was not a comparison against weekly semaglutide 2.4 mg for obesity, nor evidence of a universal winner.
Boehringer Ingelheim funded the trial.